Silencing MiRNA-1297 Suppresses the Invasion and Migration of Prostate Cancer Cells Via Targeting Modulation of PTEN and Blocking of the AKT/ERK Pathway

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2021 May 31

PMID 34055067

Citations 2

Authors

Lei Wang

Jing Gao

Yu Zhang

Shaosan Kang

Affiliations

Soon will be listed here.

Abstract

Phosphatase and tensin homolog (PTEN) loss is a major contributing factor of prostate cancer (PC). miRNA-1297 was reported to serve role in various cancer types; however, the potential roles of miRNA-1297 in PC had not been investigated. In the present study, tumor and adjacent tissues were collected from patients with PC. The gene expression level of miRNA-1297 was measured via polymerase chain reaction. Results indicated that the miRNA-1297 was overexpressed in tumor tissues from PC patients and in PC cell lines. miRNA-1297 also contributed toward the progression of PC. PTEN was confirmed as the direct target of miRNA-1297 and bound with miRNA-1297 via four binding sites. The miRNA-1297 level was negatively associated with the PTEN level. Silencing miRNA-1297 or overexpression of PTEN significantly inhibited the cell migration and invasion. In addition, the AKT/ERK pathway was also inhibited following silencing of miRNA-1297 or overexpression of PTEN. Taken together, the results indicated that silencing miRNA-1297 exerted inhibitory effects on the invasion and migration of PC cells via modulating PTEN and blocking of the AKT/ERK pathway. The results of the present study provided a novel strategy for treatment of prostate cancer cells.

Citing Articles

Impact of UV-Irradiated Mesoporous Titania Nanoparticles (mTiNPs) on Key Onco- and Tumor Suppressor microRNAs of PC3 Prostate Cancer Cells.

Mendez-Garcia A, Bravo-Vazquez L, Sahare P, Paul S Genes (Basel). 2025; 16(2).

PMID: 40004477 PMC: 11855573. DOI: 10.3390/genes16020148.

Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms.

Gujrati H, Ha S, Wang B Cancers (Basel). 2023; 15(12).

PMID: 37370750 PMC: 10296615. DOI: 10.3390/cancers15123140.

Targeting PI3K/Akt signaling in prostate cancer therapy.

Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S J Cell Commun Signal. 2022; 17(3):423-443.

PMID: 36367667 PMC: 10409967. DOI: 10.1007/s12079-022-00702-1.

References

Fazio S, Berti G, Russo F, Evangelista M, DAurizio R, Mercatanti A . The miR-28-5p Targetome Discovery Identified SREBF2 as One of the Mediators of the miR-28-5p Tumor Suppressor Activity in Prostate Cancer Cells. Cells. 2020; 9(2). PMC: 7072282. DOI: 10.3390/cells9020354. View

Cuzick J, Thorat M, Andriole G, Brawley O, Brown P, Culig Z . Prevention and early detection of prostate cancer. Lancet Oncol. 2014; 15(11):e484-92. PMC: 4203149. DOI: 10.1016/S1470-2045(14)70211-6. View

Acunzo M, Croce C . MicroRNA in Cancer and Cachexia--A Mini-Review. J Infect Dis. 2015; 212 Suppl 1:S74-7. PMC: 4574551. DOI: 10.1093/infdis/jiv197. View

Chaux A, Peskoe S, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J . Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012; 25(11):1543-9. PMC: 4380219. DOI: 10.1038/modpathol.2012.104. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Mukherjee R, Bartlett J, Krishna N, Underwood M, Edwards J . Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate. 2005; 64(1):101-7. DOI: 10.1002/pros.20211. View

Zhu Z, Wen Y, Xuan C, Chen Q, Xiang Q, Wang J . Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis. FEBS Open Bio. 2020; 10(4):674-688. PMC: 7137804. DOI: 10.1002/2211-5463.12805. View

Tutar Y . miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014; 15(5):429. DOI: 10.2174/138920101505140828161335. View

Tsai Y, Jou Y, Tsai H, Shiau A, Wu C, Tzai T . Prothymosin-α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer. Cancer Sci. 2019; 110(4):1208-1219. PMC: 6447842. DOI: 10.1111/cas.13963. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

de Bono J, De Giorgi U, Nava Rodrigues D, Massard C, Bracarda S, Font A . Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clin Cancer Res. 2018; 25(3):928-936. DOI: 10.1158/1078-0432.CCR-18-0981. View

12.

Chen Z, Zhang M, Qiao Y, Yang J, Yin Q . MicroRNA-1297 contributes to the progression of human cervical carcinoma through PTEN. Artif Cells Nanomed Biotechnol. 2018; 46(sup2):1120-1126. DOI: 10.1080/21691401.2018.1479711. View

13.

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

14.

Lu X, Xue B, Zhang T, Zhou X, Zhang Y . Down-regulation of microRNA-10a mediates the anti-tumor effect of icaritin in A549 cells via the PTEN/AKT and ERK pathway. Gen Physiol Biophys. 2019; 38(6):525-533. DOI: 10.4149/gpb_2019041. View

15.

Ullman D, Dorn D, Rais-Bahrami S, Gordetsky J . Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer. Urology. 2017; 113:59-70. DOI: 10.1016/j.urology.2017.11.022. View

16.

Sun J, Li S, Wang F, Fan C, Wang J . Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis. BMC Med Genet. 2019; 20(1):191. PMC: 6889628. DOI: 10.1186/s12881-019-0923-7. View

17.

Chen X, Zhang L, Song Q, Chen Z . MicroRNA-216b regulates cell proliferation, invasion and cycle progression via interaction with cyclin T2 in gastric cancer. Anticancer Drugs. 2020; 31(6):623-631. DOI: 10.1097/CAD.0000000000000915. View

18.

Qadir M, Faheem A . miRNA: A Diagnostic and Therapeutic Tool for Pancreatic Cancer. Crit Rev Eukaryot Gene Expr. 2017; 27(3):197-204. DOI: 10.1615/CritRevEukaryotGeneExpr.2017019494. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

20.

Van Roosbroeck K, Calin G . Cancer Hallmarks and MicroRNAs: The Therapeutic Connection. Adv Cancer Res. 2017; 135:119-149. DOI: 10.1016/bs.acr.2017.06.002. View